Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291399 | 0.90 | ALDH1A1 (0.44) | CYP3A4PKMALDH1A1KMT2AFDPS | |
| SCHEMBL28152645 | 0.84 | TSHR (0.45) | CYP3A4PKMALDH1A1KMT2AFDPS | |
| SCHEMBL28011812 | 0.83 | FDPS (0.46) | CYP3A4PKMALDH1A1KMT2AFDPS | |
| SCHEMBL12530273 | 0.80 | ALDH1A1 (0.44) | CYP3A4PKMALDH1A1KMT2AFDPS | |
| SCHEMBL6959399 | 0.78 | HTT (0.46) | CYP3A4PKMALDH1A1KMT2AMAPK1 | |
| SCHEMBL6748509 | 0.78 | FDPS (0.41) | CYP3A4PKMALDH1A1ALOX15MAPK1 | |
| SCHEMBL5900543 | 0.78 | ALDH1A1 (0.49) | PKMALDH1A1KMT2AFDPSSMN1; SMN2 | |
| Bromide SCHEMBL5529731 | 0.77 | HTT (0.45) | CYP3A4PKMALDH1A1KMT2AMAPK1 | |
| Hydrochloric Acid SCHEMBL27680689 | 0.77 | HTT (0.45) | CYP3A4PKMALDH1A1KMT2AMAPK1 | |
| SCHEMBL6296334 | 0.76 | CYP3A4 (0.34) | CYP3A4PKMALDH1A1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649767-B2 | Contacting an enamine compound with a ketonic compound in presence of a base, treating the reaction mixture thus obtained with an acid or combinations of acids | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030078430-A1 | Process for preparing 1,4-dihydropyridine compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1106615-B1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1110962-A1 | Process for preparing 1,4-dihydropyridine compounds | PFIZER INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CYP3A4 1099/4885PKM 2320/4885ALDH1A1 2124/4885 |
| US-20030078430-A1 | Process for preparing 1,4-dihydropyridine compounds | QDPR, HRH1, HRH4 | CYP3A4 33/4885PKM 520/4885ALDH1A1 463/4885 |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | CYP3A4 1180/4885PKM 1827/4885ALDH1A1 2557/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CYP3A4 938/4885PKM 1798/4885ALDH1A1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.